Lawmakers reject White House bid to politicize NIH grant decisions
Senators from both parties objected to reported White House plans to impose political reviews on NIH grant awards. Senate Appropriations Chair Susan Collins said such a move would contradict congressional intent and undermine scientific merit-based selection. The administration's effort follows a proposed rule that Congress has temporarily blocked.
The dispute centers on two separate administration actions: a proposed Uniform Guidance rule requiring political appointees to review discretionary grants against presidential priorities, and a reported plan for an executive order or White House-level review of NIH awards. Congress has already delayed the rule's implementation through a continuing resolution funding the government until mid-December, but the reported executive order effort would bypass that legislative check.
The administration's broader pattern of intervention includes terminating or freezing over 1,800 research grants last year, particularly those tied to diversity, equity, and inclusion initiatives. Officials also proposed cutting NIH's budget, capping researcher overhead costs, and installing a forward-funding process requiring full multiyear grant payments upfront—a concept lawmakers rejected. Research advocacy groups warn that political review could disrupt ongoing clinical trials and patient care.
If political criteria enter NIH funding decisions, the effects could ripple across the research enterprise—delaying clinical trials, discouraging scientists from pursuing politically sensitive topics, and potentially steering public health resources away from evidence-based priorities. Patients awaiting treatments could face setbacks, while universities and medical centers may see funding instability. Conversely, supporters argue alignment with presidential priorities could improve accountability. The bipartisan congressional pushback suggests institutional resistance, but the outcome may hinge on whether future administrations respect scientific independence or continue testing its limits.